46 results about "Riluzole" patented technology

The present invention relates to an agent for protecting a motor nerve of a patient with amyotrophic lateral sclerosis, which comprises a combination of (a) (2R)-2-propyloctanoic acid or a salt thereof and (b) a therapeutic agent for amyotrophic lateral sclerosis such as riluzole. An agent comprising a combination of (a) (2R)-2-propyloctanoic acid which is orally administered once a day in an amount per dose of about 1200 mg and (b) riluzole which is orally administered twice a day in an amount per dose of about 50 mg is useful for protecting a motor nerve in a patient(s) with amyotrophic lateral sclerosis. The agent can also suppress the respiratory disability associated with the progression of the disease condition and improve the survival rate of the patient(s).

A composition including diazoxide (7-chloro-3-methyl-2H-1,2,4-benzothiadiazine-1,1-dioxide) for the treatment and / or prevention of retinal ischemia and of diseases associated with retinal ischemia. The composition can also contain riluzole, a derivative active in neuroprotection of the latter, or a pharmaceutically acceptable salt of the latter.

Disclosed is a method of treating melanoma in a mammal comprising administering (a) a therapeutically effective amount of an inhibitor of metabotropic glutamate receptor 1 (GRM1); and (b) a therapeutically effective amount of an inhibitor of at least one downstream signaling target of GRM1. Also disclosed are compositions and kits for treating melanoma comprising (a) a therapeutically effective amount of an inhibitor of GRM1; and (b) a therapeutically effective amount of an inhibitor of at least one downstream signaling target of GRM1.

Physically and chemically stable aqueous oral suspensions of riluzole and manufacturing methods thereof. The suspensions contain riluzole in particle form and at least a wetting agent, preferably a surfactant. Riluzole is present in amounts from about 0.1% to about 20% w / v and has an average particle size lower than 200 μm. The suspensions are devoid of the known local (mouth) anaesthetic effects of riluzole.

Disclosed are methods of treating Alzheimer's Disease by administering to a patient in need thereof a riluzole prodrug such as troriluzole. Pharmaceutical compositions and kits including the riluzoleprodrugs are also disclosed.

Disclosed are methods of treating a disease in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of riluzole, or a pharmaceutically acceptable salt thereof, in the form of an oral solid molded fast-dispersing dosage form. Pharmaceutical compositions and kits are also disclosed.

Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan / quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB) / tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.

Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.

Methods and compositions for the treatment of multiple sclerosis comprising riluzole (6-(trifluoromethoxy)-benzothiazolamine) are disclosed herein.

Disclosed is a method of treating a tumor in a patient, comprising (a) administering riluzole in an amount effective to sensitize the tumor cells to ionizing radiation, and (b) irradiating the tumor cells with ionizing radiation in a dose effective to reduce tumor cell growth. The method can further comprise administering an effective amount of one or more additional therapeutic agents.

The invention relates to a riluzole orally disintegrating tablet and a preparation method thereof, belonging to the field of preparations. The tablet is prepared from riluzole, sodium bicarbonate, filler, disintegrant, lubricant and flavoring agent. The preparation method is as follows: 1) Weigh the prescribed amount of riluzole, sodium bicarbonate, filler and 50% of the prescribed amount of disintegrant, mix evenly, and prepare the mixture for later use; 2) add the mixture in step 1 to granulate with ethanol aqueous solution, and dry After sieving, the dry granules are ready for use; 3) Add 50% of the disintegrating agent of the prescribed amount and the flavoring agent of the prescribed amount to the dry granules of step 2, mix evenly, then add the lubricant of the prescribed amount, mix evenly, and compress to obtain Riluzole orally disintegrating tablet. The orally disintegrating tablet prepared by the invention has short disintegration time limit, high dissolution rate and no gritty feeling, meets the quality standard requirements of the orally disintegrating tablet, and is suitable for industrial scale-up production.

The present invention provides a method for providing neuroprotection to the central or peripheral nervous system of a subject in need of such neuroprotection, which comprises periodically administering to the subject a certain amount of glatiramer acetate and a certain amount of 2-amino-6 - Trifluoromethoxybenzothiazole, wherein said amount is effective to provide neuroprotection to said subject's central or peripheral nervous system when taken together. The present invention also provides a package comprising glatiramer acetate, 2-amino-6-trifluoromethoxybenzothiazole, and a composition for use together to provide neuroprotection to the central or peripheral nervous system of a subject in need of such neuroprotection. Neuroprotective Instructions for Use. Furthermore, the present invention provides a pharmaceutical composition comprising an amount of glatiramer acetate and an amount of 2-amino-6-trifluoromethoxybenzothiazole, wherein said amounts are effective to provide for Neuroprotection of the subject's central or peripheral nervous system. The present invention also provides a pharmaceutical combination comprising a certain amount of glatiramer acetate and a certain amount of 2-amino-6-trifluoromethoxybenzothiazole in separate dosage forms, the combination is effective for providing Neuroprotection of the central or peripheral nervous system. Additionally, the combination therapy may be used to treat a subject afflicted with multiple sclerosis or a subject afflicted with amyotrophic lateral sclerosis.